Wednesday, July 8, 2026

Drug profile · INN

safinamide mesylate

safinamide mesylate (SAFINAMIDE MESYLATE) is a monoamine oxidase b inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — safinamide mesylate
US status
approved
Class
Route
ORAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

safinamide mesylate (SAFINAMIDE MESYLATE) is a monoamine oxidase b inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN safinamide mesylate
Brand SAFINAMIDE MESYLATE
Mechanism Monoamine oxidase B inhibitor
Target Amine oxidase [flavin-containing] B
Route ORAL
Formulation TABLET

Mechanism of action

Monoamine oxidase B inhibitor

Primary target: Amine oxidase [flavin-containing] B

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. SAVE PAIN 2025 Phase 3 · Théa Pharma Ireland · PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

Related & competitor drugs

  1. rasagiline mesylate Monoamine oxidase B inhibitor
  2. safinamide Nervous system (N04)
  3. selegiline Monoamine oxidase B inhibitor
  4. selegiline hydrochloride Monoamine oxidase B inhibitor

Frequently asked questions

What is safinamide mesylate?

safinamide mesylate (SAFINAMIDE MESYLATE) is a monoamine oxidase b inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for safinamide mesylate?

SAFINAMIDE MESYLATE is a marketed brand name for safinamide mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of safinamide mesylate?

safinamide mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.